Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

DHAI vs MBOT vs ISRG vs NVCR vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DHAI
DIH Holding US, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$51K
5Y Perf.-99.8%
MBOT
Microbot Medical Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$143M
5Y Perf.+56.3%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+46.9%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-15.5%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$112.69B
5Y Perf.+0.7%

DHAI vs MBOT vs ISRG vs NVCR vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DHAI logoDHAI
MBOT logoMBOT
ISRG logoISRG
NVCR logoNVCR
SYK logoSYK
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Devices
Market Cap$51K$143M$161.07B$1.92B$112.69B
Revenue (TTM)$63M$0.00$10.58B$674M$25.12B
Net Income (TTM)$-9M$-13M$2.98B$-173M$3.25B
Gross Margin51.0%66.3%75.2%63.5%
Operating Margin-7.7%30.5%-27.2%22.4%
Forward P/E43.3x19.1x
Total Debt$12M$111K$303M$290M$14.86B
Cash & Equiv.$2M$3M$3.37B$103M$4.01B

DHAI vs MBOT vs ISRG vs NVCR vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DHAI
MBOT
ISRG
NVCR
SYK
StockFeb 24Apr 26Return
DIH Holding US, Inc. (DHAI)1000.2-99.8%
Microbot Medical In… (MBOT)100156.3+56.3%
Intuitive Surgical,… (ISRG)100146.9+46.9%
NovoCure Limited (NVCR)10084.5-15.5%
Stryker Corporation (SYK)100100.7+0.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: DHAI vs MBOT vs ISRG vs NVCR vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ISRG and SYK are tied at the top with 3 categories each (5-stock set) — the right choice depends on your priorities. Stryker Corporation is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. NVCR also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
DHAI
DIH Holding US, Inc.
The Lower-Volatility Pick

DHAI lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
MBOT
Microbot Medical Inc.
The Healthcare Pick

Among these 5 stocks, MBOT doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs SYK's 187.1%
  • Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
  • Beta 1.02, current ratio 4.87x
Best for: growth exposure and long-term compounding
NVCR
NovoCure Limited
The Momentum Pick

NVCR ranks third and is worth considering specifically for momentum.

  • +1.1% vs DHAI's -99.3%
Best for: momentum
SYK
Stryker Corporation
The Income Pick

SYK is the #2 pick in this set and the best alternative if income & stability and valuation efficiency is your priority.

  • Dividend streak 34 yrs, beta 0.55, yield 1.1%
  • PEG 1.28 vs ISRG's 1.99
  • Better valuation composite
  • Beta 0.55 vs NVCR's 2.20, lower leverage
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs MBOT's -17.1%
ValueSYK logoSYKBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs NVCR's -25.7%
Stability / SafetySYK logoSYKBeta 0.55 vs NVCR's 2.20, lower leverage
DividendsSYK logoSYK1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)NVCR logoNVCR+1.1% vs DHAI's -99.3%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs MBOT's -34.4%, ROIC 15.0% vs -6.2%

DHAI vs MBOT vs ISRG vs NVCR vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DHAIDIH Holding US, Inc.
FY 2025
Devices
79.1%$50M
Service
19.1%$12M
Other
1.8%$1M
MBOTMicrobot Medical Inc.

Segment breakdown not available.

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
NVCRNovoCure Limited

Segment breakdown not available.

SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

DHAI vs MBOT vs ISRG vs NVCR vs SYK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

SYK and MBOT operate at a comparable scale, with $25.1B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDHAI logoDHAIDIH Holding US, I…MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
RevenueTrailing 12 months$63M$0$10.6B$674M$25.1B
EBITDAEarnings before interest/tax-$4M-$14M$3.8B-$165M$6.3B
Net IncomeAfter-tax profit-$9M-$13M$3.0B-$173M$3.2B
Free Cash FlowCash after capex-$5M-$11M$2.8B-$48M$4.3B
Gross MarginGross profit ÷ Revenue+51.0%+66.3%+75.2%+63.5%
Operating MarginEBIT ÷ Revenue-7.7%+30.5%-27.2%+22.4%
Net MarginNet income ÷ Revenue-13.8%+28.2%-25.7%+12.9%
FCF MarginFCF ÷ Revenue-7.4%+26.8%-7.1%+17.1%
Rev. Growth (YoY)Latest quarter vs prior year-27.1%+23.0%+12.3%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+22.6%+62.8%+18.8%-100.0%+56.0%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

SYK leads this category, winning 5 of 7 comparable metrics.

At 35.0x trailing earnings, SYK trades at a 39% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.

MetricDHAI logoDHAIDIH Holding US, I…MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
Market CapShares × price$50,711$143M$161.1B$1.9B$112.7B
Enterprise ValueMkt cap + debt − cash$10M$140M$158.0B$2.1B$123.5B
Trailing P/EPrice ÷ TTM EPS-0.00x-2.92x57.62x-13.80x35.03x
Forward P/EPrice ÷ next-FY EPS est.43.35x19.06x
PEG RatioP/E ÷ EPS growth rate2.65x2.36x
EV / EBITDAEnterprise value multiple43.62x20.31x
Price / SalesMarket cap ÷ Revenue0.00x16.00x2.92x4.49x
Price / BookPrice ÷ Book value/share9.44x9.17x5.51x5.02x
Price / FCFMarket cap ÷ FCF64.67x26.31x
SYK leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 7 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs MBOT's 3/9, reflecting solid financial health.

MetricDHAI logoDHAIDIH Holding US, I…MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
ROE (TTM)Return on equity-37.1%+16.9%-50.8%+15.0%
ROA (TTM)Return on assets-32.4%-34.4%+14.8%-16.5%+6.9%
ROICReturn on invested capital-6.2%+15.0%-16.4%+11.4%
ROCEReturn on capital employed-2.9%+16.5%-28.9%+13.0%
Piotroski ScoreFundamental quality 0–933656
Debt / EquityFinancial leverage0.03x0.02x0.85x0.66x
Net DebtTotal debt minus cash$10M-$3M-$3.1B$187M$10.8B
Cash & Equiv.Liquid assets$2M$3M$3.4B$103M$4.0B
Total DebtShort + long-term debt$12M$111,000$303M$290M$14.9B
Interest CoverageEBIT ÷ Interest expense-21.37x-96.80x6.72x
ISRG leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — MBOT and ISRG each lead in 2 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $9 for DHAI. Over the past 12 months, NVCR leads with a +1.1% total return vs DHAI's -99.3%. The 3-year compound annual growth rate (CAGR) favors MBOT at 22.8% vs DHAI's -90.3% — a key indicator of consistent wealth creation.

MetricDHAI logoDHAIDIH Holding US, I…MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
YTD ReturnYear-to-date+837.5%+0.9%-19.3%+28.3%-15.2%
1-Year ReturnPast 12 months-99.3%-15.1%-15.4%+1.1%-22.5%
3-Year ReturnCumulative with dividends-99.9%+85.2%+49.6%-75.7%+5.5%
5-Year ReturnCumulative with dividends-99.9%-69.7%+58.7%-91.3%+21.5%
10-Year ReturnCumulative with dividends-99.9%-99.4%+554.2%+30.3%+187.1%
CAGR (3Y)Annualised 3-year return-90.3%+22.8%+14.4%-37.6%+1.8%
Evenly matched — MBOT and ISRG each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — DHAI and NVCR each lead in 1 of 2 comparable metrics.

DHAI is the less volatile stock with a -1.13 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs DHAI's 0.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDHAI logoDHAIDIH Holding US, I…MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 500-1.21x1.90x1.00x2.15x0.52x
52-Week HighHighest price in past year$8.99$4.67$603.88$20.06$404.87
52-Week LowLowest price in past year$0.00$1.60$427.84$9.82$289.91
% of 52W HighCurrent price vs 52-week peak+0.3%+45.6%+75.1%+83.9%+72.7%
RSI (14)Momentum oscillator 0–10038.146.342.469.824.3
Avg Volume (50D)Average daily shares traded2K1.5M1.8M1.5M2.1M
Evenly matched — DHAI and NVCR each lead in 1 of 2 comparable metrics.

Analyst Outlook

SYK leads this category, winning 1 of 1 comparable metric.

Analyst consensus: MBOT as "Buy", ISRG as "Buy", NVCR as "Buy", SYK as "Buy". Consensus price targets imply 158.2% upside for MBOT (target: $6) vs 32.4% for SYK (target: $390). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.

MetricDHAI logoDHAIDIH Holding US, I…MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$5.50$622.60$33.50$389.62
# AnalystsCovering analysts3551550
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises034
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%0.0%0.0%
SYK leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SYK leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 2 of 6 categories
Loading custom metrics...

DHAI vs MBOT vs ISRG vs NVCR vs SYK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is DHAI or MBOT or ISRG or NVCR or SYK a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -2. 5% for DIH Holding US, Inc. (DHAI). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Microbot Medical Inc. (MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — DHAI or MBOT or ISRG or NVCR or SYK?

On trailing P/E, Stryker Corporation (SYK) is the cheapest at 35.

0x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Stryker Corporation is actually cheaper at 19. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — DHAI or MBOT or ISRG or NVCR or SYK?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -99. 9% for DIH Holding US, Inc. (DHAI). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus DHAI's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — DHAI or MBOT or ISRG or NVCR or SYK?

By beta (market sensitivity over 5 years), DIH Holding US, Inc.

(DHAI) is the lower-risk stock at -1. 21β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately -278% more volatile than DHAI relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — DHAI or MBOT or ISRG or NVCR or SYK?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -2. 5% for DIH Holding US, Inc. (DHAI). On earnings-per-share growth, the picture is similar: Microbot Medical Inc. grew EPS 30. 5% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — DHAI or MBOT or ISRG or NVCR or SYK?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is DHAI or MBOT or ISRG or NVCR or SYK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 1x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 24. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MBOT: 158. 2% to $5. 50.

08

Which pays a better dividend — DHAI or MBOT or ISRG or NVCR or SYK?

In this comparison, SYK (1.

1% yield) pays a dividend. DHAI, MBOT, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.

09

Is DHAI or MBOT or ISRG or NVCR or SYK better for a retirement portfolio?

For long-horizon retirement investors, DIH Holding US, Inc.

(DHAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -1. 21)). Microbot Medical Inc. (MBOT) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHAI: -99. 9%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between DHAI and MBOT and ISRG and NVCR and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DHAI is a small-cap quality compounder stock; MBOT is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while DHAI, MBOT, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DHAI

Quality Business

  • Sector: Healthcare
  • Market Cap > $2B
  • Gross Margin > 30%
Run This Screen
Stocks Like

MBOT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.